Duvelisib and Abametapir: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 11, 2026 · Source data updated Jun 30, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Abametapir
No brand names on recordDuvelisib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Abametapir is a lotion used to treat head lice. Even though it's applied to your scalp, a little gets into your body and can briefly block a liver enzyme (called CYP3A4) that breaks down other medicines. Duvelisib (Copiktra), your cancer medicine, is cleared by that same enzyme.
When abametapir slows that enzyme, more duvelisib can build up in your body, which may raise the risk of its side effects. This is based on how the drugs work rather than on strong studies, but because duvelisib is a serious medication, it's worth taking seriously. Please don't change anything on your own. Let your pharmacist or doctor know you use both so they can guide you safely.
Mechanism: Abametapir is a potent CYP3A4 inhibitor. Duvelisib is a CYP3A4 substrate, so concomitant use raises duvelisib exposure (increased AUC/Cmax).
- Direction: increased duvelisib exposure, greater risk of dose-related toxicity (e.g., hepatotoxicity, diarrhea/colitis, infections, neutropenia).
- Onset: rapid; inhibition can persist, so effects extend for up to 2 weeks after a single topical application.
- Evidence: theoretical, based on established CYP3A4 pharmacology.
- Management: Avoid CYP3A4 substrates such as duvelisib within 2 weeks of abametapir application; if that is not feasible, avoid abametapir. Coordinate timing and monitor closely if co-exposure occurs.
What happens
Increased exposure of CYP3A4 substrate
Interaction Deep Dive
Do not administer CYP3A4 substrates during the 2 weeks that follow abametapir application. Should avoiding these substrates not be possible, abametapir itself should be avoided1.
Why it happens (mechanism)
Inhibition of CYP3A4-mediated metabolism by abametapir
How to manage this interaction
The good news: this is very manageable with timing. Abametapir is a one-time lice treatment, so the main strategy is spacing the two apart.
- Your care team will typically avoid using a CYP3A4 substrate like duvelisib within 2 weeks after applying abametapir.
- If that gap isn't feasible, they may choose to avoid abametapir and use another lice treatment instead.
- If both are used close together, expect closer monitoring for duvelisib side effects.
What to do: keep taking duvelisib as prescribed and tell your pharmacist or prescriber before using any lice treatment so they can plan the timing for you.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Duvelisib and Abametapir together?
Abametapir can raise duvelisib levels and side-effect risk, so keep them apart: avoid duvelisib (or other CYP3A4 medicines) for 2 weeks after applying abametapir, and ask your care team to plan the timing. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Duvelisib and Abametapir interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "rapid". Effects can appear quickly, often within about 24 hours of combining the drugs.
How is the Duvelisib and Abametapir interaction managed?
The good news: this is very manageable with timing. Abametapir is a one-time lice treatment, so the main strategy is spacing the two apart. Your care team will typically avoid using a CYP3A4 substrate like duvelisib within 2 weeks after applying abametapir. If that gap isn't feasible, they may choose to avoid abametapir and use another lice treatment instead. If both are used close together, expec… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Duvelisib or Abametapir need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: XEGLYZE(TM) topical lotion, abametapir topical lotion. Dr Reddy’s Laboratories Inc (per FDA), Princeton, NJ, 2020. DailyMed
Keep reading about Abametapir
Keep reading about Duvelisib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist